HCAT

Health Catalyst is a sub-scale healthcare data-analytics vendor whose GAAP numbers look catastrophic but whose operating reality is more mixed. The FY2025 net loss of -$178M and -72.4% ROE are alarming on the surface, yet the MD&A attributes the bulk of the deterioration to a $105.4M non-cash goodwill impairment 'primarily due to overall declines in our stock price and market capitalization' — a mark-to-sentiment charge, not cash out the door. Strip it (and $50.5M of D&A) and the underlying trend is actually improving: management-reported Adjusted EBITDA rose to $41.4M from $26.1M (2024) and $11.0M (2023), and operating cash flow stayed positive at $731K. At $2.08 the market cap is just $153M against $311M of revenue — a 0.5x P/S — so the price already discounts a great deal of the bad news.

The problem is the top line has flat-lined. Revenue grew only +1.5% to $311M, the tail end of a clear deceleration (242→276→296→307→311), and management is explicit that OBBBA — signed July 4, 2025, projected to cut ~$1T of federal Medicaid spending over ten years — is elongating sales cycles, pushing Life Sciences opportunities, and has already 'negatively impacted our 2025 bookings achievement and our expectations for revenue in 2026.' A data-analytics platform whose provider clients are facing budget strain is guiding to more of its bookings coming from upsells to the existing base, which rarely reaccelerates growth. On top of that it competes against Epic, Oracle Health, Optum Analytics and IBM — larger, better-financed rivals — in an 'intensely competitive' market with pricing pressure.